Working... Menu

EXIBIT: Oxaliplatin in Biliary Tract Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00174564
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : February 17, 2012
Information provided by (Responsible Party):

Brief Summary:

The primary objective is to evaluate the efficacy of the GEMOX treatment as 1st line therapy in patients with advanced biliary tract cancer based on response rate measured by the RECIST unidimensional criteria.

Secondary objectives are : Progression free survival, overall survival and safety.

Condition or disease Intervention/treatment Phase
Biliary Tract Neoplasms Drug: oxaliplatin Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 67 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicentre Phase II Trial of Gemcitabine and Oxaliplatin (GEMOX) in Patients With Biliary Tract Cancer
Study Start Date : April 2003
Actual Primary Completion Date : September 2006
Actual Study Completion Date : September 2006

Resource links provided by the National Library of Medicine

Drug Information available for: Oxaliplatin

Primary Outcome Measures :
  1. To evaluate response rate according to RECIST criteria

Secondary Outcome Measures :
  1. To evaluate the progression-free survival in the ITT population
  2. To investigate safety using NCI-CTC criteria version 2

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Histologically proven, locally advanced or metastatic carcinoma of the biliary tract (gallbladder, intrahepatic bile ducts, extrahepatic bile ducts, ampula of Vater)
  • For intrahepatic bile ducts, if the diagnosis of biliary tract origin is not evident by imaging or surgical exploration, and so equivalent to liver metastasis with unknown primary site, inclusion is possible if:

    • unknown primary after an exhaustive search for the primary site (chest radiography- , thoracic and abdomino pelvic CT scan, colonoscopy, oesogastroduodenal endoscopy, PSA determination for men or mammography for women, and PET scan if possible).
    • histological examination compatible with adenocarcinoma of bile ducts with the immunostaining expression of cytokeratin : 7+, 20- and 19 +. (Shimonishi, 2000 ^22)
  • No prior chemotherapy for advanced disease (first line)
  • No radiation therapy within 4 weeks prior to the first gemcitabine administration.
  • Unidimensionally measurable disease.
  • For female patient of childbearing potential, neither pregnant nor breastfeeding, and under active contraception
  • No known allergy to one of the study drugs
  • No prior malignancy
  • No CNS metastases
  • No peripheral neuropathy > grade 2
  • ECOG PS <=2
  • ANC > 1.5 X 10^9 /L
  • Platelets > 100 X 10^9 /L
  • Creatinine < 1.5 x ULN
  • SGPT (ALT) < 5 x ULN
  • Bilirubin < 2.5 x ULN (patients with jaundice or evidence of bile duct obstruction and in whom the biliary tree can be decompressed by endoscopic percutaneous endoprothesis, with subsequent reduction in bilirubin < 2.5 x ULN will be eligible for the study).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00174564

Sponsors and Collaborators
Layout table for investigator information
Study Director: Jean-Philippe Aussel Sanofi

Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT00174564     History of Changes
Other Study ID Numbers: C_8552
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: February 17, 2012
Last Verified: February 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Biliary Tract Diseases
Digestive System Diseases
Antineoplastic Agents